The Speak Foundation

The Speak Foundation
The Speak Foundation
  • Home
  • About Us
  • Limb-Girdle Magazine
  • LGMD Patient Network
  • Scientific Workshop
  • PFDD
  • Be the Hope Campaign
  • Donate
  • Advocacy
  • Programs
    • GLOBAL ADVOCACY SUMMIT
    • LGMD CONFERENCE
    • LGMD EDUCATION
    • GRANT PROGRAMS
  • Partnerships
  • Contact Us
  • More
    • Home
    • About Us
    • Limb-Girdle Magazine
    • LGMD Patient Network
    • Scientific Workshop
    • PFDD
    • Be the Hope Campaign
    • Donate
    • Advocacy
    • Programs
      • GLOBAL ADVOCACY SUMMIT
      • LGMD CONFERENCE
      • LGMD EDUCATION
      • GRANT PROGRAMS
    • Partnerships
    • Contact Us
  • Sign In

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • About Us
  • Limb-Girdle Magazine
  • LGMD Patient Network
  • Scientific Workshop
  • PFDD
  • Be the Hope Campaign
  • Donate
  • Advocacy
  • Programs
    • GLOBAL ADVOCACY SUMMIT
    • LGMD CONFERENCE
    • LGMD EDUCATION
    • GRANT PROGRAMS
  • Partnerships
  • Contact Us

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

EL-PFDD Meeting For Six Subtypes of LGMD

On September 23, 2022, a coalition of limb-girdle muscular dystrophy (LGMD) organizations held an Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for six LGMD subtypes: 2C (R5), 2D (R3), 2E (R4), 2F (R6), 2A (R1), and 2i (R9). The LGMD Coalition includes the following organizations: Coalition to Cure Calpain 3, CureLGMD2i, Kurt+Peter Foundation, LGMD2D Foundation, McColl-Lockwood Laboratory for Muscular Dystrophy Research, and the Speak Foundation. 


The goal of this meeting was to provide the U.S. Food and Drug Administration (FDA), product developers, clinicians, industry, and academic researchers an opportunity to hear perspectives from individuals with LGMD on the health effects, daily impacts, treatment goals, and decision factors considered when seeking out or selecting a treatment. This meeting was  conducted as a parallel effort to FDA’s EL-PFDD initiative, a commitment under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V) to more systematically gather patients’ perspectives on their conditions and available therapies to treat their conditions.


Please note that this initial endeavor represented Phase 1 and included six LGMD subtypes.  We anticipate additional LGMD subtypes will pursue EL-PFDD meetings in the future.

Below on this page you can view the  recorded footage of the meeting or read the summary of the meeting in our Voice of the Patient (VOP) report. You can also find more information about this EL-PFDD meeting at this link: 

I want more information

LGMD EL-PFDD REPLAY

Watch the first ever Limb-Girdle Muscular Dystrophy Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting held on September 23, 2023.

VOICE OF THE PATIENT REPORT

The is the Voice of the Patient (VOP)Report, which provides a detailed summary of the outcomes of the EL-PFDD meeting. 

Download PDF

Our LGMD Coalition

Our Sponsors

Thank you to our panelists!

We are so grateful to everyone who participated in the 

EL-PFDD on September 23rd!

Download PDF

Copyright © 2008 The Speak Foundation

The Limb Girdle Muscular Dystrophy Foundation

All Rights Reserved.

Powered by

  • LGMD Patient Network
  • Contact Us

Sign Up Today!

Sign up to be included in the Limb Girdle Muscular Dystrophy Patient Network where you will receive cutting edge research updates from the leading experts in the world such as the GRASP LGMD consortium and also be invited to hear about new clinical trials.  When you sign up here, you will also receive the free LGMD News Magazine if you live in the USA.  Anyone can join the LGMD Patient Network.